AI주식인사이트AI Stock Insight
B

경남제약

053950KOSDAQ의약품 제조업

56.3 / 100

Reference Date: 2026-04-13

Financial Score18.5 / 40
News Sentiment12.8 / 25
Momentum15.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 14.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Gyeongnam Pharmaceutical primarily operates in the manufacturing and sales of pharmaceuticals, raw materials, and health functional foods, distributing products like Lemona, Jaha Saengryeok, and Minol. In 2025, revenue reached 55.9 billion won, a decrease of approximately 8% compared to the previous period, though the Lemona food product line continues to show steady growth. The company is expanding its business through online marketing and broadening its distribution channels.

Number of Employees

238people

Average Salary

53.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 14.804.0Point
PBR
0.56Industry Average 1.045.5Point

Lower than industry avg (good)

ROE
-8.06Industry Average 4.420.0Point

Well below industry avg

Debt Ratio
1.01Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼9.6% (2-year basis)

Operating Profit Growth Rate
1.0 / 3

Avg ▲1.2% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -7.9% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 0Neutral 1Negative 0Average Sentiment Score 55

Detailed Momentum

52-week position5.0Point

52w mid range (51%)

Current 772Won52-week high 96552-week low 564
1-month return5.0Point

1m +14.88% (rising)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral전환가액의조정2026-04-10
  • Neutral주권매매거래정지 (주식의 병합, 분할 등 전자등록 변경, 말소)2026-04-09
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-27
  • Neutral사업보고서 (2025.12)2026-03-18